Christel Aperlo Iffland
About Christel Aperlo Iffland
Christel Aperlo Iffland serves as the Vice President of Antibody Technologies at Ligand Pharmaceuticals, where she has worked since 2017. With extensive experience in antibody discovery and a strong background in display technologies, she has held various significant roles in the biotechnology sector, including positions at Emd Serono and Dana-Farber Cancer Institute.
Current Role at Ligand Pharmaceuticals
Christel Aperlo Iffland serves as Vice President of Antibody Technologies at Ligand Pharmaceuticals. She has held this position since 2017, contributing to the company's focus on innovative therapeutic solutions. Her role involves overseeing the development of antibody technologies, particularly in oncology and immuno-oncology. Iffland's leadership is pivotal in advancing the company's research and development initiatives.
Previous Experience at Emd Serono, Inc.
Prior to her current role, Iffland worked at Emd Serono, Inc. for six years as Associate Director of Antibody Technologies from 2011 to 2017. She also held positions as Group Leader of Antibody Screening and Senior Scientist II in Phage Technology during her tenure there. Her work focused on advancing antibody discovery methodologies and technologies, significantly impacting the organization's research capabilities.
Academic Background and Education
Iffland studied at Université Nice Sophia Antipolis, where she earned her Master's degree in 1993. She continued her education at the same institution, obtaining a Doctor of Philosophy in Philosophy between 1994 and 1997. This academic foundation supports her expertise in scientific research and development within the biotechnology sector.
Expertise in Antibody Discovery and Technologies
Iffland possesses strong knowledge in display technologies, including phage and yeast display, which are critical for antibody discovery. She specializes in developing antibodies for oncology and immuno-oncology targets. Her expertise extends to managing teams focused on therapeutic antibody discovery, demonstrating her leadership in the field.
Research Contributions and Innovations
Throughout her career, Iffland has led significant scientific developments, including the OmniAb platform, which is essential for antibody discovery. She has extensive experience utilizing OmniRats and OmniFlic transgenic rats for human IgG expression. These contributions highlight her role in advancing antibody technologies and therapeutic applications.